LycoRed, a science-based Israeli company with over 15 years of experience, claims Parry infringed upon three patents, violating the company’s science on the composition, process and applications for lycopene products. The lawsuit was filed in US District Court, District of New Jersey, for infringement of US Patents 6,515,018, 5,837,311 and 5,965,183.
LycoRed alleges that Parry/Valensa engaged in acts of infringement by making, using and selling its tomato lycopene products in the US, and has therefore placed its customers in the position of doing so as well.
LycoRed is asking the court to grant an injunction to stop sales of, and to recall, all products that infringe on the noted patents and to award damages to compensate the company for the unlawful violations.
Morris Zelkha, president and CEO of LycoRed, said: “Parry Nutraceuticals unlawfully leveraged our proprietary science to produce and market its tomato lycopene complex. Parry, however, has not offered any scientific research to demonstrate that its lycopene products have the same clinical attributes as Lyc-O-Mato.”
Lyc-O-Mato has a unique patented particle size of less than five microns and is supported by clinical studies demonstrating high bioavailability and absorption, the company said.
Source: LycoRed
© FoodBev Media Ltd 2024